Monoclonal B lymphocytosis - Revision history

John at 20:26, 18 June 2023

2023-06-18T20:26:30Z

← Older revision		Revision as of 22:26, 18 June 2023
Line 15:		Line 15:
	<font color="navy">1. Flow cytometry defined features:</font>		<font color="navy">1. Flow cytometry defined features:</font>

	*Evidence that there is a monoclonal population of B lymphocytes (this can be based on ~~their~~ light chain ~~retriction~~ or abnormal ~~phenotype~~ features)		*Evidence that there is a monoclonal population of B lymphocytes (this can be based on restricted light chain expression, or on abnormal phenotypic features)

	*A profile of by flow cytometry that suggests either CLL or other LPD, based on the abnormal gated population that may be a minority of cells		*A profile of by flow cytometry that suggests either CLL or other LPD, based on the abnormal gated population that may be a minority of cells

John at 20:25, 18 June 2023

2023-06-18T20:25:16Z

← Older revision		Revision as of 22:25, 18 June 2023
Line 2:		Line 2:


	Monoclonal B-lymphocytosis (MBL) as a distinct entity recognised in the WHO Classification ~~and~~ used to denote the presence of abnormal clonal B-cells in blood, but with counts that do not meet the diagnostic criteria for CLL or other LPD. This is an important distinction since affected individauals are not regarded as having a lymphoproliferative disorder, although they may experience some symptoms, and ~~the disease~~ may progress.		Monoclonal B-lymphocytosis (MBL) as a distinct entity recognised in the WHO Classification. The term is used to denote the presence of abnormal clonal B-cells in blood, but with counts that do not meet the diagnostic criteria for CLL or other LPD. This is an important distinction since affected individauals are not regarded as having a lymphoproliferative disorder, although they may experience some symptoms and may progress to a CLL or other lymphoma.

	~~The diagnosis is suggested from flow cytometry of blood. The~~ report should record the count of abnormal lymphocytes and refer to the phenotype of the cells identifying them as either "CLL phenotype" or "non-CLL phenotype" based on the flow cytometry profile~~, but it~~ is important also that the report reflects the need for additional clinical confirmation (see below).		A report should record the count of abnormal lymphocytes, and should refer to the phenotype of the cells identifying them as either "CLL phenotype" or "non-CLL phenotype" based on the flow cytometry profile. It is important also however that the report reflects the need for additional clinical confirmation (see below).

	----		----

John at 20:23, 18 June 2023

2023-06-18T20:23:07Z

← Older revision		Revision as of 22:23, 18 June 2023
Line 2:		Line 2:


	Monoclonal B-lymphocytosis (MBL) as a distinct entity recognised in the WHO Classification and used to denote the presence of abnormal ~~conal~~ B-cells that do not meet the diagnostic criteria for CLL or other LPD ~~based~~. It is an important distinction since affected ~~individaual~~ are not regarded as having a lymphoproliferative disorder, although they may experience some symptoms, and the disease may progress.		Monoclonal B-lymphocytosis (MBL) as a distinct entity recognised in the WHO Classification and used to denote the presence of abnormal clonal B-cells in blood, but with counts that do not meet the diagnostic criteria for CLL or other LPD. This is an important distinction since affected individauals are not regarded as having a lymphoproliferative disorder, although they may experience some symptoms, and the disease may progress.

	The diagnosis is suggested from flow cytometry of blood~~, but always requires clinical confirmation - it is important that reports reflect the need for additional clinical conformation~~. The report should refer to the phenotype of the cells identifying either "CLL phenotype" or "non-CLL phenotype" based on the flow cytometry profile.		The diagnosis is suggested from flow cytometry of blood. The report should record the count of abnormal lymphocytes and refer to the phenotype of the cells identifying them as either "CLL phenotype" or "non-CLL phenotype" based on the flow cytometry profile, but it is important also that the report reflects the need for additional clinical confirmation (see below).

	----		----
Line 19:		Line 19:
	*A profile of by flow cytometry that suggests either CLL or other LPD, based on the abnormal gated population that may be a minority of cells		*A profile of by flow cytometry that suggests either CLL or other LPD, based on the abnormal gated population that may be a minority of cells

	*A count of abnormal cells that is <~~1x10~~<sup>9</sup> for the abnormal ~~poulation~~ (usually calculated from the gated abnormal poulation and the absolute lymphocyte count		*A count of abnormal cells that is <5x10<sup>9</sup> for the abnormal population (usually calculated from the gated abnormal poulation and the absolute lymphocyte count


Line 26:		Line 26:

	<font color="navy">2. Clinical evidence that there is no detectable evidence of tissue disease or its effects:</font>		<font color="navy">2. Clinical evidence that there is no detectable evidence of tissue disease or its effects:</font>

			*The abnormal count should be present for >3 months

	*No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells		*No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells

John at 14:08, 18 June 2023

2023-06-18T14:08:25Z

← Older revision		Revision as of 16:08, 18 June 2023
Line 9:		Line 9:


	Diagnosis is made from '''blood''' assessment by flow cytometry and is based on the following criteria that are both flow cytometric ~~AND~~ clinical:		Diagnosis is made from '''blood''' assessment by flow cytometry and is based on the following criteria that are both flow cytometric '''and''' clinical:

John at 14:07, 18 June 2023

2023-06-18T14:07:51Z

← Older revision		Revision as of 16:07, 18 June 2023
Line 25:		Line 25:


	<font color="navy">~~'''~~2. Clinical evidence that there is no detectable evidence of tissue disease or its effects:~~'''~~</font>		<font color="navy">2. Clinical evidence that there is no detectable evidence of tissue disease or its effects:</font>

	*No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells		*No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells

John at 14:07, 18 June 2023

2023-06-18T14:07:26Z

← Older revision		Revision as of 16:07, 18 June 2023
Line 22:		Line 22:


	~~'''~~AND~~'''~~		AND


	<font color="navy">'''2. ~~'''~~Clinical evidence~~'''~~ that there is no detectable evidence of tissue disease or its effects:'''</font>		<font color="navy">'''2. Clinical evidence that there is no detectable evidence of tissue disease or its effects:'''</font>

	*No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells		*No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells

John at 14:06, 18 June 2023

2023-06-18T14:06:59Z

← Older revision		Revision as of 16:06, 18 June 2023
Line 20:		Line 20:

	*A count of abnormal cells that is <1x10<sup>9</sup> for the abnormal poulation (usually calculated from the gated abnormal poulation and the absolute lymphocyte count		*A count of abnormal cells that is <1x10<sup>9</sup> for the abnormal poulation (usually calculated from the gated abnormal poulation and the absolute lymphocyte count


	'''AND'''		'''AND'''


	<font color="navy">'''2. '''Clinical evidence''' that there is no detectable evidence of tissue disease or its effects:'''</font>		<font color="navy">'''2. '''Clinical evidence''' that there is no detectable evidence of tissue disease or its effects:'''</font>

John at 14:06, 18 June 2023

2023-06-18T14:06:40Z

← Older revision		Revision as of 16:06, 18 June 2023
Line 4:		Line 4:
	Monoclonal B-lymphocytosis (MBL) as a distinct entity recognised in the WHO Classification and used to denote the presence of abnormal conal B-cells that do not meet the diagnostic criteria for CLL or other LPD based. It is an important distinction since affected individaual are not regarded as having a lymphoproliferative disorder, although they may experience some symptoms, and the disease may progress.		Monoclonal B-lymphocytosis (MBL) as a distinct entity recognised in the WHO Classification and used to denote the presence of abnormal conal B-cells that do not meet the diagnostic criteria for CLL or other LPD based. It is an important distinction since affected individaual are not regarded as having a lymphoproliferative disorder, although they may experience some symptoms, and the disease may progress.

	The diagnosis is suggested from flow cytometry of blood, but always requires clinical confirmation - it is important that reports reflect the need for additional clinical conformation.		The diagnosis is suggested from flow cytometry of blood, but always requires clinical confirmation - it is important that reports reflect the need for additional clinical conformation. The report should refer to the phenotype of the cells identifying either "CLL phenotype" or "non-CLL phenotype" based on the flow cytometry profile.

	----		----
Line 15:		Line 15:
	<font color="navy">1. Flow cytometry defined features:</font>		<font color="navy">1. Flow cytometry defined features:</font>

	*Evidence that there is a ~~'''~~monoclonal population of B lymphocytes~~'''~~ (this can be based on their light chain retriction or abnormal phenotype features)		*Evidence that there is a monoclonal population of B lymphocytes (this can be based on their light chain retriction or abnormal phenotype features)

	*A profile of by ~~'''~~flow cytometry that suggests either CLL or other LPD~~'''~~, based on the abnormal gated population that may be a minority of cells		*A profile of by flow cytometry that suggests either CLL or other LPD, based on the abnormal gated population that may be a minority of cells

	*A ~~'''~~count of abnormal cells that is <1x10<sup>9</sup> for the abnormal poulation~~'''~~ (usually calculated from the gated abnormal poulation and the absolute lymphocyte count		*A count of abnormal cells that is <1x10<sup>9</sup> for the abnormal poulation (usually calculated from the gated abnormal poulation and the absolute lymphocyte count

	'''AND'''		'''AND'''

John at 14:04, 18 June 2023

2023-06-18T14:04:08Z

← Older revision		Revision as of 16:04, 18 June 2023
Line 21:		Line 21:
	*A '''count of abnormal cells that is <1x10<sup>9</sup> for the abnormal poulation''' (usually calculated from the gated abnormal poulation and the absolute lymphocyte count		*A '''count of abnormal cells that is <1x10<sup>9</sup> for the abnormal poulation''' (usually calculated from the gated abnormal poulation and the absolute lymphocyte count

			'''AND'''

			<font color="navy">'''2. '''Clinical evidence''' that there is no detectable evidence of tissue disease or its effects:'''</font>
	<font color="navy">'''2. '''~~Additional clinical~~ evidence''' that there is no ~~significant~~ tissue disease:'''</font>

	*No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells		*No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells

John at 14:02, 18 June 2023

2023-06-18T14:02:54Z

← Older revision		Revision as of 16:02, 18 June 2023
Line 9:		Line 9:


	Diagnosis is made from '''blood''' assessment by flow cytometry and is based on the following criteria:		Diagnosis is made from '''blood''' assessment by flow cytometry and is based on the following criteria that are both flow cytometric AND clinical:



	<font color="navy">~~'''~~1. Flow cytometry defined features:~~'''~~</font>		<font color="navy">1. Flow cytometry defined features:</font>

	*Evidence that there is a '''monoclonal population of B lymphocytes''' (this can be based on their light chain retriction or abnormal phenotype features)		*Evidence that there is a '''monoclonal population of B lymphocytes''' (this can be based on their light chain retriction or abnormal phenotype features)